Ankylosing Spondylitis
ORIGINAL PAPER
A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis
A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis
Ankylosing Spondylitis
Expected trial readout: 2025-02-19
What the evidence supports so far
Research signals
Classification pending.
What remains unverified
The full methodology, effect size, and limitations still require analyst review.
Company impact remains unverified until a direct economic transmission is established.